2 unknown, 1 active not recruiting, 1 completed, 1 withdrawn. 2 Phase 2, 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Hepatocyte Growth Factor: new trials by email Literature Review of Hepatocyte Growth Factor trials Research Report on Hepatocyte Growth Factor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar KP-100LI, Placebo - Vocal Fold Scar | Phase 3 | Active not recruiting | Kringle Pharma, Inc. | 62 | 2022-12-01 | 2026-07-06 |
| Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia Avatrombopag, Standard medical treatment - Liver Failure, Thrombocytopenia | Phase 4 | Unknown | Tongji Hospital | 150 | 2021-02-01 | 2021-06-07 |
| Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury KP-100IT - Acute Spinal Cord Injury | Phase 3 | Unknown | Kringle Pharma, Inc. | 25 | 2020-07-13 | 2022-08-26 |
| Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea Stage 1-Low dose VM202RY, Stage 1-Middle dose VM202RY, Stage 1-High dose VM202RY - Ischemic Heart Disease, Acute Myocardial Infarction | Phase 2 | Withdrawn | Helixmith Co., Ltd. | 2018-01-25 | 2025-09-25 | |
| Phase I/II Study of KP-100IT in Acute Spinal Cord Injury KP-100IT, Placebo - Spinal Cord Injuries | Phase 1 / Phase 2 | Completed | Kringle Pharma, Inc. | 45 | 2014-06-30 | 2019-06-05 |
Deafness, Autosomal Recessive 39 (3) · End Stage Liver Disease (1) · Liver Failure (1) · Myocardial Ischemia (1) · Spinal Cord Injuries (1) · Thrombocytopenia (1)
Kringle Pharma, Inc. (3) · Helixmith Co., Ltd. (1) · Tongji Hospital (1)
Japan (3) · China (1) · South Korea (1)
Daichika Hayata (1) · Etsuro Hashimura (1) · Qin Ning, MD., PhD. (1) · Wook Bum Pyun, MD, PhD (1)